NCT04298749View on ClinicalTrials.gov

Safety and Tolerability of GX-P1 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

June 7, 2021

Study Completion Date

June 7, 2021

Conditions
Autoimmune Diseases
Interventions
DRUG

GX-P1 or Placebo (dose level 1)

GX-P1 dose level 1 or placebo

DRUG

GX-P1 or Placebo (dose level 2)

GX-P1 dose level 2 or placebo

DRUG

GX-P1 or Placebo (dose level 3)

GX-P1 dose level 3 or placebo

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT04298749 - Safety and Tolerability of GX-P1 in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter